| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TNFRSF13C; BAFFR; CVID4; BAFF-R; BROMIX; prolixin |
| Entrez GeneID | 115650 |
| clone | 5A9B10 |
| WB Predicted band size | 18.9kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD268 (AA: extra 1-78) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD268(TACI)抗体的模拟参考文献示例(内容为虚构，仅供格式参考)：
1. **标题**：*Targeting CD268 (TACI) with a Novel Monoclonal Antibody Suppresses B-Cell Proliferation in Autoimmune Disorders*
**作者**：Smith A, et al.
**摘要**：研究报道了一种新型抗CD268单克隆抗体，可特异性结合TACI受体，抑制过度活化的B细胞增殖，在类风湿性关节炎模型中显著减轻炎症反应。
2. **标题**：*CD268 Antibody Enhances Vaccine Efficacy by Modulating Plasma Cell Differentiation*
**作者**：Li J, et al.
**摘要**：通过动物实验证明，抗CD268抗体通过调节TACI-BAFF/APRIL信号通路，促进抗原特异性浆细胞分化，增强疫苗诱导的免疫应答。
3. **标题**：*Therapeutic Anti-CD268 Antibody Reverses Immune Dysregulation in Systemic Lupus Erythematosus*
**作者**：Garcia R, et al.
**摘要**：临床前研究表明，靶向CD268的抗体可减少SLE模型小鼠的自身抗体产生，改善肾脏病理损伤，提示其治疗红斑狼疮的潜力。
4. **标题**：*Structural Characterization of a Humanized Anti-CD268 Antibody for Multiple Myeloma Therapy*
**作者**：Wang Y, et al.
**摘要**：该研究解析了人源化抗CD268抗体的晶体结构，证明其通过阻断APRIL配体结合抑制多发性骨髓瘤细胞存活，为临床试验奠定基础。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed。)
The CD268 antibody targets the CD268 antigen, also known as TNFRSF13B or TACI (Transmembrane Activator and CAML Interactor), a cell-surface receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). TACI is primarily expressed on B lymphocytes and plays a critical role in regulating B-cell activation, differentiation, and immune tolerance. It binds to two ligands, BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), to mediate signaling pathways involved in antibody production, class-switch recombination, and plasma cell survival. Dysregulation of TACI signaling has been implicated in autoimmune disorders (e.g., systemic lupus erythematosus), immunodeficiency syndromes (e.g., common variable immunodeficiency, CVID), and B-cell malignancies.
CD268 antibodies are engineered to either agonize or antagonize TACI activity, depending on therapeutic goals. Antagonistic antibodies may suppress pathogenic B-cell responses in autoimmune diseases, while agonistic forms could enhance immune responses in cancer or infections. Research on CD268 antibodies has expanded due to their potential to modulate humoral immunity with precision. For instance, preclinical studies explore their use in targeting autoreactive B cells or sensitizing malignant B cells to apoptosis. However, challenges remain in optimizing specificity and minimizing off-target effects. Overall, CD268 antibodies represent a promising tool for both understanding B-cell biology and developing targeted therapies for immune-related disorders.
×
